Tolebrutinib slows disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (MS).

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

Experimental drug shows promise for advanced MS, delaying disability. Learn how Black Americans may benefit & why clinical ...

Sanofi’s tolebrutinib has been shown to delay disability progression in multiple sclerosis (MS) patients, according to phase ...

Tolebrutinib, an experimental drug, slowed disability progression in advanced MS by 31% in a major trial, offering hope for ...

Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine ...

Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...